Biogen and City Therapeutics to develop RNAi therapy
Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging tissue-enhanced delivery technologies, the …
Post
-
-
How the cell and gene therapy market is taking shape
Cell and gene therapy (C>) represents a major advance in medical treatments by directly targeting the root causes of diseases …
-
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout
Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big …
-
Capitalising on UK’s goal to become a world-leading clinical trial destination
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following …
-
GSK makes new drug submission for depemokimab in Canada
GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific conditions. The …
-
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout
Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big …
-
Capitalising on UK’s goal to become a world-leading clinical trial destination
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following …
-
GSK makes new drug submission for depemokimab in Canada
GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific conditions. The …
-
What’s been agreed at this year’s World Health Assembly?
With the 78th World Health Assembly ending today, all eyes have been on this year’s World Health Organization (WHO) member’s …
-
Lupin partners SteinCares to commercialise biosimilar in LATAM
Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American markets, excluding …
-
FDA to review Otsuka’s sibeprenlimab application for IgAN
The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for sibeprenlimab for review. The monoclonal …
-
Pharmaceutical Technology Excellence Awards 2025: Upperton Pharma Solutions
Upperton Pharma Solutions (Upperton), a contract development and manufacturing organization (CDMO) based in the UK, won the Business Expansion award …
-
EMA validates Soleno’s application for Prader-Willi syndrome treatment
The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) submitted by Soleno Therapeutics for diazoxide choline prolonged-release …
-
China’s CDE grants breakthrough status approval to Abbisko’s HCC therapy
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted breakthrough therapy designation approval to Abbisko …
-
CHMP recommends GSK’s Blenrep approval for multiple myeloma treatment
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep …
